Roche drug sets new treatment standard for KRAS-driven lung cancer

A new drug from Roche has set a new standard of care for KRAS-driven lung cancer, one of the most common and hard-to-treat mutations in oncology. KRAS was long considered an "undruggable" target. The full findings are reported by STAT News behind its STAT+ paywall.